Attovia Therapeutics, Inc. (NASDAQ:ATTO) Stock Short Interest Report for September

Attovia Therapeutics, Inc. (NASDAQ:ATTO) was the target of a large growth in short interest during the month of September. As of September 30th, there was short interest totaling 1,649,612 shares, a growth of 98.5% from the September 15th total of 831,090 shares. Approximately 3.6% of the shares of the company are short sold. Based on an average trading volume of 553,841 shares, the days-to-cover ratio is presently 3.0 days.

Attovia Therapeutics Stock Performance

NASDAQ ATTO traded down $0.01 on Wednesday, hitting $14.71. 12,349 shares of the company were exchanged, compared to its average volume of 346,782. The stock’s fifty day moving average is $20.33. Attovia Therapeutics has a 12 month low of $14.23 and a 12 month high of $28.00. The stock has a market capitalization of $671.51 million and a P/E ratio of -3.01.

Attovia Therapeutics (NASDAQ:ATTO) last issued its earnings results on Wednesday, September 2nd. The company reported ($4.88) EPS for the quarter. The firm had revenue of $0.45 million during the quarter. As a group, research analysts anticipate that Attovia Therapeutics will post -4.06 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ATTO. Wall Street Zen upgraded Attovia Therapeutics to a “sell” rating in a research note on Saturday, September 19th. Leerink Partners assumed coverage on shares of Attovia Therapeutics in a research report on Monday, August 31st. They set an “outperform” rating and a $52.00 price objective for the company. Citigroup began coverage on Attovia Therapeutics in a report on Monday, August 31st. They issued a “buy” rating and a $30.00 target price for the company. Royal Bank Of Canada assumed coverage on shares of Attovia Therapeutics in a research note on Monday, August 31st. They set an “outperform” rating and a $45.00 price target for the company. Finally, Morgan Stanley began coverage on Attovia Therapeutics in a research report on Monday, August 31st. They set an “overweight” rating and a $39.00 price objective for the company. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $42.20.

Insider Transactions at Attovia Therapeutics

In other news, Director Colin Walsh purchased 500,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was acquired at an average cost of $17.00 per share, with a total value of $8,500,000.00. Following the acquisition, the director owned 3,020,632 shares in the company, valued at approximately $51,350,744. This trade represents a 19.84% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Life Sciences Xi L.P. Frazier purchased 588,235 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $9,999,995.00. Following the completion of the transaction, the insider owned 6,154,213 shares of the company’s stock, valued at $104,621,621. This trade represents a 10.57% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders acquired 2,740,587 shares of company stock valued at $47,269,979.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc is a clinical-stage biotechnology company developing antibody-based medicines for immune-mediated and inflammatory diseases. The company uses proprietary antibody-engineering technologies to design therapies intended to modulate biological pathways involved in chronic inflammation.

Attovia’s development pipeline includes ATTO-1310, an investigational antibody therapy being advanced for atopic dermatitis and potentially other inflammatory conditions. The company’s broader research efforts focus on developing treatments that may offer targeted activity and durable effects for patients with immune-related diseases.

Attovia Therapeutics is advancing its programs through preclinical and clinical development and has not yet established a commercial product portfolio.